Clinical trials: Genital Neoplasm, Female
Cervical Cancer
Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
This is a multicenter, open-label phase I/II study in patients with advanced cervical cancer designed to evaluate the safety, tolerability, and preliminary efficacy of ZG005 in combination with Gecacitinib ± bevacizumab.
- Trial name
- NCT07080216
- Testing
- ZG005, Gecacitinib, Bevacizumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Polycystic Ovary Syndrome, Infertility, Female
Comparison of Ovulation Induction Cycle Outcomes Between Early and Late Dose Increments for Low Dose Gonadotropin Step-up Protocol Among Infertile Women Diagnosed With Polycystic Ovary Syndrome: Prospective Randomised Trial
Low dose gonadotropin step-up ovulation induction treatment is the universally accepted and utilized teratment protocol for infertile women diagnosed with polycystic ovary syndrome (PCOS).
- Trial name
- NCT04528849
- Testing
- Gonadotropin dose increment timing
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Ovarian Cancer
Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer
Thirty-seven women aged 18-75 years with recurrent ovarian cancer were enrolled
- Trial name
- NCT06188455
- Testing
- Fluzoparib Capsules, Apatinib Mesylate Tablets
- Volunteers
- 37 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Precancerous Lesions, Conization
A Cohort Study for the Following up of Conization
This study is to investigate the oncologic and obstetric outcomes in patients with conization for uterine cervical lesions from January 1, 2000 to January 1, 2019 in Peking Union Medical College Hospital.
- Conditions
- Precancerous Lesions, Conization, High Grade Intraepithelial Neoplasia, Uterine Cervical Cancer
- Trial name
- NCT03961178
- Testing
- High-risk HPV, TCT
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Lei Li
Cervical Dysplasia
Correlation Between Colposcopist Findings and Digital Cervicography Employing Gynescope System
Correlation between colposcopist findings and digital cervicography employing Gynescope system
- Trial name
- NCT03840187
- Testing
- Digital cervicography
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Barzilai Medical Center
Breast Cancer, Ovarian Cancer
Methods in Education for Breast Cancer Genetics
In 1997, the Genetics Department of the NCI Medicine Branch helped establish a breast cancer genetics program at the National Naval Medical Center s Breast Care Center.
- Trial name
- NCT00001806
- Testing
- Genetic Education and Counseling
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Ovarian Cancer
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability and determine the MTD to subsequently define an RP2D of alisertib in combination with weekly paclitaxel in East Asian participants with advanced solid tumors.
- Conditions
- Advanced Solid Tumors, Ovarian Cancer, Small Cell Lung Cancer
- Trial name
- NCT02367352
- Testing
- Alisertib, Paclitaxel
- Where
- 3 sites in Japan, South Korea
- Volunteers
- 9 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum
Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer
This study evaluates the safety, tolerability, and preliminary anti-tumor activity of EB-DUALNK, a dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy, in adults with recurrent or refractory epithelial…
- Trial name
- EB-DUALNK-OV (NCT07589543)
- Testing
- EB-DUALNK, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Cancer., Melanoma.
Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)
This study is a clinical trial phase I/II. Its goal is to determine the safety, tolerability, immunogenicity and efficacy of a therapeutic vaccine with the tumor antigen NY-ESO-1 combined with the adjuvant MPLA from B.
- Conditions
- Cancer., Melanoma., Ovarian Cancer., Lung Cancer.
- Trial name
- NCT01584115
- Testing
- NY-ESO-1 combined with MPLA, NY-ESO-1 combined with MPLA vaccine
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Instituto de Investigação em Imunologia
Ovarian Cancer
Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer
This study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy Paclitaxel and Carboplatin with Pembrolizumab in patients with advanced ovarian cancer.
- Trial name
- MITO28MaNGOov4 (NCT03410784)
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 13 sites in Italy
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute, Naples
Kidney Cancer, Melanoma (Skin)
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer…
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00003308
- Testing
- stereotactic radiosurgery
- Where
- 14 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Minimal Residual Disease, KRAS G12D
A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors
This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide [Amph-CpG-7909] plus a mixture of lipid-conjugated peptide-based antigens [Amph-Peptides])…
- Conditions
- Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D
- Trial name
- AMPLIFY-201 (NCT04853017)
- Testing
- ELI-002 2P
- Where
- 10 sites in United States
- Volunteers
- 25 people
- Sponsor
- Elicio Therapeutics
Ovarian Cancer
Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer
The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.
- Trial name
- NCT00345540
- Testing
- NOV-002, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellectar Biosciences, Inc.
Vulvar Cancer, Vulvar Intraepithelial Neoplasia
The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence
In vulvar neoplasia, even minor surgical interventions cause multiple symptoms, symptom distress and complications, which have an impact on a woman's quality of life and contribute to high health care costs.
- Trial name
- WOMAN-PROII (NCT01986725)
- Testing
- standardized care (Intervention I), Standardized care + WOMAN-PRO II program (Intervention II)
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- St.Gallen University of Applied Sciences
Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN)
Epidemiological Factors and Optimization of Conservative Approaches to Precancerous Lesions of Female Reproductive Organs
The primary aim of this study is to develop a recommended clinical practice guideline for managing women with HPV HR (high-risk human papillomavirus) positivity and cervical lesions.
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN), Risk Factors, Conservative Management
- Trial name
- NCT06967740
- Where
- Czechia
- Volunteers
- 200 people
- Sponsor
- Nikola Janovska
Epithelial Ovarian Cancer
Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer
Background: Previous findings have indicated antineoplastic properties of tinzaparin (Innohep®), a commonly used anti-coagulant.
- Trial name
- NCT05284552
- Testing
- Tinzaparin Injectable Solution
- Where
- 8 sites in Sweden
- Volunteers
- 40 people
- Sponsor
- University Hospital, Linkoeping
Ovarian Neoplasms, Breast Neoplasms
Establishment of a Tumor Bank for Blood Samples
Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Neoplasms of the Female Genitalia
- Trial name
- NCT01763125
- Testing
- Blood collection
- Where
- 6 sites in Austria, Belgium and 2 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin and paclitaxel with or without pembrolizumab in treating patients with…
- Trial name
- NCT07198074
- Testing
- Bevacizumab, Biospecimen Collection, Carboplatin
- Where
- 304 sites in United States
- Volunteers
- 255 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
Background: Carboplatin is approved by the Food and Drug Administration to treat cancer. AZD2281 is an experimental drug in a class of agents called PARP inhibitors.
- Trial name
- NCT01445418
- Testing
- AZ2281 + Carboplatin
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Metastatic Cervical Cancer
A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
This is a study to evaluate the efficacy and safety of TQB2450 injection in the treatment of PD-L1 positive recurrent or metastatic cervical cancer.
- Trial name
- NCT04623333
- Testing
- TQB2450
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.